Yes, in February 2026, the FDA approved Ozempic as the new proprietary name for the oral semaglutide tablet formulations of 1.5 mg, 4 mg, and 9 mg for adults with T2DM
During menopause, your hormones change and throw off any established routines you may have had, often resulting in unwanted weight gain
Add the Precision Peptide Genetic Test ($298) to optimize your personalized therapy
Notably, a clinical study demonstrated that T2DM patients receiving insulin therapy experienced significantly higher rates of pancreatitis compared to those treated with GLP-1RAs, and notably, no pancreatitis cases have been reported in clinical trials of the novel GLP-1RA Cotadutide, indicating that a comprehensive risk assessment of GLP-1RAs for pancreatic cancer remains premature pending additional data on these novel medications [8]
When shared with your provider during insurance discussions, this data can strengthen medical necessity arguments by documenting biological factors underlying your weight and metabolic profile